- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Kathy Oubre Explains How Biosimilar Savings Help Dispel Clinician Worries
Kathy Oubre, MS, chief operating officer of Pontchartrain Cancer Center, explains how biosimilars are helping to rid clinicians of their worries about the affordability of biologic drugs.
Kathy Oubre, MS, chief operating officer of Pontchartrain Cancer Center, explains how biosimilars helping to rid worries about the affordability of biologic drugs helps clinicians.
Transcript:
How much of a relief to clinicians is it to have biosimilars for expensive reference products available?
Oubre: So, when talking about biosimilars within our organization, we often use the phrase "quality without compromise." And biosimilars have really helped kind of check that box because it allows us and our providers to provide the same high quality care to our patients, while decreasing some of that financial impact to them.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.
